Significantly impaired shoulder function in the first years of rheumatoid arthritis: a controlled study

Table 2 Disease characteristics of the patients

Variable	Patients (n = 103)
Disease duration (months)	20.3 (8.5)
Disease duration (months)	19.0 (6.0; 36.0)
DAS28, 0–10	3.82 (1.37)
	3.87 (1.00; 7.41)
	n = 96
Rheumatoid factor positive, yes	81 (78.6 %)
Anti-CCP, yes	74 (75.5 %)
Anti-CCP, yes	n = 98
Rheumatoid arthritis erosions, yes	39 (39.8 %)
DMARDs	91 (89.2 %)
Anti-TNF treatment	14 (13.6 %)
Health Assessment Questionnaire, 0–3	0.60 (0.55)
	0.50 (0.00; 2.63)
	n = 102

For categorical variables, number (percentage) is presented. For continuous variables, mean (standard deviation) or median (minimum; maximum) per participant is presented
anti-CCP anti-cyclic citrullinated peptide, DAS28 DAS28, Disease Activity Score of 28 joints, DMARD disease-modifying anti-rheumatic drug, TNF tumour necrosis factor

ISSN: 1478-6362